Brief: Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid Aav-Slb101
17/11/2025 13:12
Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES ANNOUNCES LICENSING AGREEMENT WITH ANDELYN BIOSCIENCES FOR THE USE OF PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101 SOLID BIOSCIENCES INC - GRANTS ANDELYN LICENSE TO UTILIZE AAV-SLB101 SOLID BIOSCIENCES INC - AAV-SLB101 WELL TOLERATED IN 23 PARTICIPANTS IN CLINICAL TRIAL Source text: ID:nGNXDGf4N Further company coverage: SLDB.O
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs